Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 19/20 | 0.74 |
| ▸ | MAP2K2 | P36507 | 16/20 | 0.74 |
| ▸ | PIM1 | P11309 | 1/20 | 0.62 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.62 |
| ▸ | BRAF | P15056 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.56 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.56 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29781367 | 1.00 | MAP2K1 (0.74) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL6138222 | 0.90 | MAP2K1 (0.60) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL4819057 | 0.89 | MAP2K1 (0.69) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL29781350 | 0.89 | MAP2K1 (0.76) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL15698773 | 0.86 | MAP2K1 (0.59) | MAP2K1MAP2K2PIM1CAMK2BMAPK1 | |
| SCHEMBL6315390 | 0.86 | MAP2K1 (0.78) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL25143268 | 0.86 | MAP2K1 (0.72) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL30793061 | 0.86 | MAP2K1 (0.72) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL24196113 | 0.86 | MAP2K1 (0.55) | MAP2K1MAP2K2PIM1CAMK2BBRAF | |
| SCHEMBL18713284 | 0.85 | MAP2K1 (0.53) | MAP2K1MAP2K2PIM1CAMK2BMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160221975-A1 | NOVEL ANTHRANILIC AMIDES AND THE USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-08-04 | — | — | US | claimed |
| EP-3043790-A1 | NOVEL ANTHRANILIC AMIDES AND THE USE THEREOF | The Administrators of the Tulane Educational Fund (US) | 2016-07-20 | — | — | EP | claimed |
| WO-2015038743-A9 | NOVEL ANTHRANILIC AMIDES AND THE USE THEREOF | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2015-05-14 | — | — | WO | claimed |
| WO-2015038743-A1 | NOVEL ANTHRANILIC AMIDES AND THE USE THEREOF | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2015-03-19 | — | — | WO | claimed |
| CN-117642166-A | Combination therapy for cancer treatment | 中外制药株式会社 | 2024-03-01 | — | — | CN | disclosed |
| US-20230100458-A1 | NOVEL ANTHRANILIC AMIDES AND THE USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-03-30 | — | — | US | disclosed |
| WO-2023003014-A1 | METHOD FOR PRODUCING ARYLAMIDE DERIVATIVE | 中外製薬株式会社 | 2023-01-26 | — | — | WO | disclosed |
| US-11465978-B2 | Anthranilic amides and the use thereof | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2022-10-11 | — | — | US | disclosed |
| EP-3043790-B1 | NOVEL ANTHRANILIC AMIDES AND THE USE THEREOF | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2021-05-26 | — | — | EP | disclosed |
| EP-3043790-B1 | NOVEL ANTHRANILIC AMIDES AND THE USE THEREOF | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2021-05-26 | — | — | EP | disclosed |
| US-10654792-B2 | Carboxylic acid ester prodrug inhibitors of MEK | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2020-05-19 | — | — | US | disclosed |
| US-20170096388-A1 | CARBOXYLIC ACID ESTER PRODRUG INHIBITORS OF MEK | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2017-04-06 | — | — | US | disclosed |
| WO-2015038743-A1 | NOVEL ANTHRANILIC AMIDES AND THE USE THEREOF | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2015-03-19 | — | — | WO | disclosed |
| WO-2015038743-A1 | NOVEL ANTHRANILIC AMIDES AND THE USE THEREOF | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2015-03-19 | — | — | WO | disclosed |
| US-7078438-B2 | N-(4 substituted phenyl)-anthranilic acid hydroxamate esters | WARNER-LAMBERT COMPANY (US) | 2006-07-18 | — | — | US | disclosed |
| US-20050137263-A1 | N-(4 substituted phenyl)-anthranilic acid hydroxamate esters | WARNER-LAMBERT COMPANY, LLC | 2005-06-23 | — | — | US | disclosed |
| US-6891066-B2 | N-(4-substituted phenyl)-anthranilic acid hydroxamate esters | WARNER-LAMBERT COMPANY (US) | 2005-05-10 | — | — | US | disclosed |
| EP-1467968-A1 | N-(4-SUBSTITUTED PHENYL)-ANTHRANILIC ACID HYDROXAMATE ESTERS | Warner-Lambert Company LLC (US) | 2004-10-20 | — | — | EP | disclosed |
| US-20040006245-A1 | N-(4-substituted phenyl)-anthranilic acid hydroxamate esters | REWCASTLE GORDON WILLIAM (NZ) | 2004-01-08 | — | — | US | disclosed |
| WO-2003062191-A1 | N-(4-SUBSTITUTED PHENYL)-ANTHRANILIC ACID HYDROXAMATE ESTERS | WARNER-LAMBERT COMPANY LLC (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096388-A1 | CARBOXYLIC ACID ESTER PRODRUG INHIBITORS OF MEK | BRAF, MAPK1, KRAS | MAP2K1 37/4885MAP2K2 44/4885PIM1 247/4885 |
| US-20160221975-A1 | NOVEL ANTHRANILIC AMIDES AND THE USE THEREOF | API5, MAPKAPK5, MAP3K5 | MAP2K1 346/4885MAP2K2 152/4885PIM1 2026/4885 |
| US-20230100458-A1 | NOVEL ANTHRANILIC AMIDES AND THE USE THEREOF | API5, MAPKAPK5, MAP3K5 | MAP2K1 315/4885MAP2K2 144/4885PIM1 1919/4885 |
| US-20050137263-A1 | N-(4 substituted phenyl)-anthranilic acid hydroxamate esters | PAH, EGLN3, PAOX | MAP2K1 4555/4885MAP2K2 4495/4885PIM1 4241/4885 |
| US-11465978-B2 | Anthranilic amides and the use thereof | MAPKAPK5, MAP3K5, API5 | MAP2K1 301/4885MAP2K2 149/4885PIM1 1728/4885 |
| US-20040006245-A1 | N-(4-substituted phenyl)-anthranilic acid hydroxamate esters | HCAR2, EGLN3, AADAC | MAP2K1 4692/4885MAP2K2 4611/4885PIM1 4391/4885 |
| US-10654792-B2 | Carboxylic acid ester prodrug inhibitors of MEK | BRAF, MAPK1, KRAS | MAP2K1 37/4885MAP2K2 44/4885PIM1 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.